Merck’s Personalized Melanoma Vaccine Cuts Risk 49%, Advances to Phase 3
Merck’s intismeran autogene personalized melanoma vaccine cut recurrence or death risk by 49% over a five-year follow-up and maintained a 0.51 hazard ratio from three to five years. Phase 3 trials are ongoing for melanoma and non-small-cell lung cancer with interim melanoma data expected later this year.
1. Vaccine Efficacy Data
Merck’s intismeran autogene personalized melanoma vaccine, co-developed with Moderna, demonstrated a 49% reduction in the risk of recurrence or death over five years of follow-up. The hazard ratio remained at 0.51, matching the three-year result and suggesting durable immune surveillance beyond the treatment period.
2. Ongoing Phase 3 Trials
Phase 3 trials are under way for both melanoma and non-small-cell lung cancer, enrolling patients at multiple sites globally. Interim results from the melanoma trial are anticipated later this year, providing a potential catalyst for Merck’s oncology pipeline.
3. Commercial Potential
Analysts project pricing similar to Keytruda at approximately $200,000 per patient, which could drive multibillion-dollar peak sales in melanoma alone. Merck’s established Keytruda franchise enhances the market opportunity for combination therapy and revenue growth.
4. Competitive Context
Merck and Moderna lead the mRNA cancer vaccine space ahead of competitors like BioNTech-Genentech, supported by over 120 mRNA oncology trials globally. The broader mRNA therapeutics market reached about $7.7 billion in 2025 and is poised for significant expansion as clinical programs advance.